Immunocan, the Shanghai-based biotechnology firm dedicated to building innovative antibody drug discovery platforms, has secured $37.0M in Series A funding. The company, founded in 2020, leverages proprietary gene editing technology to develop animal platforms capable of generating human and alpaca antibodies.
This specialized approach aims to empower global antibody drug R&D, offering versatile tools for a range of discovery scenarios. The capital infusion marks a significant step for Immunocan as it continues its work.












